Covid19-Sources

Review clinical data on the use of ivermectin for the treatment of COVID-19.

Dr. Sucharit Bhakdi und seine Frau Dr. Karina Reiss haben wunderbare Neuigkeiten. Sie berichten begeistert von jüngst veröffentlichten Studienergebnissen, die, wie sie sagen, die entscheidende Nachricht des Jahres beinhalten: "Alle Menschen haben bereits die so gewünschte Herdenimmunität. Nicht 75% der Personen, sondern über 90% – ohne, dass man impfen muss." "Also das, was die Impfung eigentlich bewerkstelligen sollte, hat der menschliche Körper schon gebildet?", frage ich nach. – "Das haben diese Studien gezeigt!" An diesem Tag der Freude, wie der Immunologe ihn nennt, sprechen die beiden Wissenschaftler mit mir über das Prinzip der erworbenen Immunität, Antikörper, über schützende Lymphozyten, und das vortrainierte Immunsystem. Gegen den Irrweg der Impfkampagne erheben Bhakdi und Reiss schwere Vorwürfe, ebenso wie gegen die verkommenen Institutionen dieses Landes. Ein Land, in dem man zwar seine Meinung äußern kann, dann jedoch mit entsprechenden Strafmaßnahmen zu rechnen hat. Ein Land, welches sie verlassen werden, falls ihr letzter Ausweg scheitert: die politische Initiative. Prof. Dr. Sucharit Bhakdi ist deutscher Facharzt für Infektionsepidemiologie und Mikrobiologie. Er studierte Humanmedizin an der Universität Bonn, war bis zu seinem Ruhestand Professor an der Universität Mainz und leitete bis dahin das Institut für medizinische Mikrobiologie und Hygiene. Seine wissenschaftlichen Forschungen wurden mehrfach ausgezeichnet. Prof. Dr. Karina Reiss ist deutsche Biochemikerin und Hochschullehrerin. Sie promovierte und habilitierte an der Medizinischen Fakultät der Universität Kiel, im Fach Biochemie. Beide sind Eltern eines gemeinsamen Sohnes. Im Gespräch erwähnte Studien: Studie 1: Spikes were produced in and ejected from cells in contact with the bloodstream.(https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075) Studie 2: Circulating, specific SARS-CoV-2 IgG and IgA antibodies became detectable 1-2 weeks after application of mRNA vaccines. (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499, https://doi.org/10.1016/j.cell.2021.06.005) Studie 3: SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. (https://www.sciencedirect.com/science/article/pii/S2352396421002036) Studie 4: Spike-specific IgG and IgA levels rise further one day after second injection of mRNA (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499) Karina Reiss, Sucharit Bhakdi: Corona unmasked. Neue Daten, Zahlen, Hintergründe. https://bit.ly/35MeFai Reiss/Bhakdi: Corona Fehlalarm? Zahlen, Daten und Hintergründe. https://bit.ly/3d43sG7 Eine FILMPRODUKTION von Tobias Jansen und Lukas Karl Website http://jansen-film.de http://lukomotiv.de YouTube https://www.youtube.com/tobiasjansen https://youtube.com/LuKaPhotography Instagram https://instagram.com/tobsjans https://instagram.com/luko.motiv YOUTUBE Gunnar Kaiser: https://www.youtube.com/c/gunnarkaisertv YOUTUBE Gunnar Kaiser Unchained: https://www.youtube.com/user/philosophischleben VIMEO https://vimeo.com/gunnarkaiser LBRY https://lbry.tv/@kaisertv:a RUMBLE https://rumble.com/user/GunnarKaiser WEBSITE http://www.gunnarkaiser.de BLOG http://www.kaisertv.de TELEGRAM https://t.me/gunnarkaisertv TWITTER https://twitter.com/GunnarKaiser MERCHANDISING https://gunnarkaiser.com/ PODCAST iTunes https://goo.gl/dNuWVF Spotify https://goo.gl/qBVZvy Soundcloud https://goo.gl/rHhkg1 Mein Projekt REFUGIUM: https://youtu.be/LX0ZKtyrI4E Mein Roman "Unter der Haut": https://bit.ly/32NZnkt EXKLUSIV Über 100 exklusive Videos und Artikel sowie alle Informationen zu Vorträgen, Seminaren und Lesungen ab einem Euro im Monat: - KaiserTV-Kanalmitgliedschaft: https://bit.ly/35diV1x - Substack: https://gunnarkaiser.substack.com - Patreon: https://www.patreon.com/gunnarkaiser UNTERSTÜTZEN: KONTO: Gunnar Kaiser; IBAN DE38 3704 0044 0162 5706 00 PAYPAL: http://www.paypal.me/gunnarkaiser BITCOIN bc1qumd4n2wez42r8fp5qxqtf2u8edn2vwsz3nt4a8 1J8bPrXymYYcPN9Fkc6QFyxA4UfCJWh2rS BITCOIN CASH qpz6njg2h08vqwdqhw39vy3a5wxhwxykngs2hrzawm DASH XwPQi8PtevRgLzWsXhwtRcGe6unQFbQ7yS MONERO 44SP24XRF7b3sGNo3ejq93BL2SvniLWZ3QbFYH78VJiLDLayeaCX1AsakzK3piMh5B4skzhARzw1BQNe5EDJb7Bf59AL7eQ

Almost half of children who contract covid-19 may have lasting symptoms, which should factor into decisions on reopening schools, reports Helen Thomson

When will vaccines for children be available? ➡️ Pfizer anticipates having initial results of lower-dose Phase 2/3 trials in September for 5- to 11-year-old kids; results for kids 2-<5 shortly after; kids 6-<24 months old in October or November. #COVID19 https://t.co/F1dEYZNhZt

Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, despite being relatively young and having only mild to moderate acute COVID-19 symptoms.

Key Points. The RBD of SARS-CoV-2 shares sequence similarity with an ancient lectin family known to bind blood group antigens.SARS-CoV-2 RBD binds the blood gro

Transparenz ist der Schlüssel für Vertrauen in Impfstoffe. Die in Deutschland gemeldeten Verdachtsfälle von Nebenwirkungen oder Impfkomplikationen im zeitlichen Zusammenhang mit der Impfung gegen COVID-19 erfasst und bewertet das Paul-Ehrlich-Institut kontinuierlich. Das Ergebnis finden Sie in unserem aktuellen Sicherheitsbericht für den Zeitraum vom 27.12.2020 bis 30.04.2021.

Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, despite being relatively young and having only mild to moderate acute COVID-19 symptoms.

Objective To estimate changes in life expectancy in 2010-18 and during the covid-19 pandemic in 2020 across population groups in the United States and to compare outcomes with peer nations. Design Simulations of provisional mortality data. Setting US and 16 other high income countries in 2010-18 and 2020, by sex, including an analysis of US outcomes by race and ethnicity. Population Data for the US and for 16 other high income countries from the National Center for Health Statistics and the Human Mortality Database, respectively. Main outcome measures Life expectancy at birth, and at ages 25 and 65, by sex, and, in the US only, by race and ethnicity. Analysis excluded 2019 because life table data were not available for many peer countries. Life expectancy in 2020 was estimated by simulating life tables from estimated age specific mortality rates in 2020 and allowing for 10% random error. Estimates for 2020 are reported as medians with fifth and 95th centiles. Results Between 2010 and 2018, the gap in life expectancy between the US and the peer country average increased from 1.88 years (78.66 v 80.54 years, respectively) to 3.05 years (78.74 v 81.78 years). Between 2018 and 2020, life expectancy in the US decreased by 1.87 years (to 76.87 years), 8.5 times the average decrease in peer countries (0.22 years), widening the gap to 4.69 years. Life expectancy in the US decreased disproportionately among racial and ethnic minority groups between 2018 and 2020, declining by 3.88, 3.25, and 1.36 years in Hispanic, non-Hispanic Black, and non-Hispanic White populations, respectively. In Hispanic and non-Hispanic Black populations, reductions in life expectancy were 18 and 15 times the average in peer countries, respectively. Progress since 2010 in reducing the gap in life expectancy in the US between Black and White people was erased in 2018-20; life expectancy in Black men reached its lowest level since 1998 (67.73 years), and the longstanding Hispanic life expectancy advantage almost disappeared. Conclusions The US had a much larger decrease in life expectancy between 2018 and 2020 than other high income nations, with pronounced losses among the Hispanic and non-Hispanic Black populations. A longstanding and widening US health disadvantage, high death rates in 2020, and continued inequitable effects on racial and ethnic minority groups are likely the products of longstanding policy choices and systemic racism. Data sharing: Requests for additional data and analytic scripts used in this study should be emailed to RKM (Ryan.Masters@colorado.edu).

This cross-sectional study examines the association of the COVID-19 pandemic with estimated life expectancy by race/ethnicity in the US.

Despite poor protection after two shots, an extra dose helps some

Background An increasing number of reports have described the COVID-19 associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus stat...

"I feel guilty because I know I brought it home from work and at the time we were told it doesn’t affect children. To be ill for over a year when you’re only 10 - that’s a tenth of your life.”

This cross-sectional study uses administrative health care data on 2.9 million households from the first 45 weeks of 2020 to assess the association between social gatherings and SARS-CoV-2 transmission by studying whether COVID-19 rates increase after birthdays in a household.

Die Maskenpflicht anpassen ja, abschaffen keinesfalls, kommentiert Lars Fischer

The global race to develop a COVID-19 vaccine is on. Here are the different types of vaccines and how your body uses them to develop immunity.

Northern town of Binyamina-Giv'at Ada says contagion appeared to come from people who arrived from abroad; school won't open Sunday, the last day of classes before summer

The 1st direct antiviral drug intervention—monoclonal antibody cocktail—to improve covid survival Preprint of #RECOVERY https://t.co/21Kf4Gl2Mg Benefit in hospitalized patients who have not developed an antibody response; potential harm in those who had https://t.co/l2fXJtd3yJ https://t.co/EqrXqbl0Rg

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. While many vaccines have been deployed to date, the continual evolution of the viral receptor-binding domain (RBD) has challenged their efficacy. In particular, emerging variants B.1.1.7 (U.K.), B.1.351 (South Africa) and P.1 (Brazil) have compromised convalescent sera and immunotherapies that received emergency use authorization1–3. One potential alternative to avert viral escape is the use of camelid VHHs or nanobodies, which can recognize epitopes often inaccessible to conventional antibodies4. Here, we isolate anti-RBD nanobodies from llamas and “nanomice” we engineered to produce VHHs cloned from alpacas, dromedaries and camels. We identified two sets of highly neutralizing nanobodies. Group 1 circumvents antigenic drift by recognizing an RBD region that is highly conserved in coronaviruses but rarely targeted by human antibodies. Group 2 is almost exclusively focused to the RBD-ACE2 interface and fails to neutralize variants carrying E484K or N501Y substitutions. Notably however, group 2 nanobodies retain full neutralization activity against variants when expressed as homotrimers, rivaling the most potent antibodies produced to date against SARS-CoV-2. These findings suggest that multivalent nanobodies overcome SARS-CoV-2 mutations through two separate mechanisms: enhanced avidity for the ACE2 binding domain, and recognition of conserved epitopes largely inaccessible to human antibodies. Therefore, while new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised.

On May 19, 2021, the Delta Variant of Concern (VOC), formerly known as the Indian VOC or B 1.617.2, became the dominant strain of SARS-CoV-2 in Scotland. The Alpha VOC (formerly known as the Kent VOC, B.1.1.7, or S gene negative) had been the dominant strain previously, but it has rapidly been replaced (appendix p 1).

New outbreak in 44 kids at a middle school in Israel 🇮🇱 with #DeltaVariant, the second such outbreak at a school this week—both Delta. Several fully vaccinated adults also infected at school. 🇮🇱 also recently stop requiring #COVID19 tests upon arrival. 🧵 https://t.co/ikH54y5aSe https://t.co/KyM0JcE5SH

Literaturübersicht zur Wirksamkeit von Masken, Stand 20-11-2020

The COVID-19 pandemic is seemingly driving birthrates down – but it's not the only thing behind the global fertility decline. Here's what's behind it and why it matters.

The global race to develop a COVID-19 vaccine is on. Here are the different types of vaccines and how your body uses them to develop immunity.

But in the days following the start of the vaccination campaign, a new development became evident: Several of the recently vaccinated HCWs developed symptoms of Covid-19, and an infection with SARS-CoV-2 was confirmed by PCR. Of the 1306 HCWs who had received a first dose of the vaccine by January 18th, 2021, seven HCWs tested positive. A symptomatic infection was confirmed on day two, four, seven, eleven, sixteen, seventeen and nineteen after receiving the first dose, respectively. The recently vaccinated made up 35% of the total number of the 20 employees of the University Hospital who tested positive in that time period, meaning the recently vaccinated were overrepresented among those with a symptomatic infection. Of those who had been inoculated and later tested positive, some may have already been in the incubation period when receiving the vaccine, but others likely became infected shortly after receiving the first dose.

With the COVID-19 pandemic now ongoing for close to a year, people all over the world are still waiting for a vaccine to become available. The initial…

The authors explore how seasonal variation in transmissibility could modulate a SARS-CoV-2 pandemic. The likely aggregated effect of seasonal variation, infection control measures, and transmission rate variation is a prolonged pandemic wave with lower prevalence at any given time, thereby providing a window of opportunity for better preparation of health care systems.

Superspreading complicates the study of SARS-CoV-2 transmission. I propose a model for aggregated case data that accounts for superspreading and improves statistical inference. In a Bayesian...

While seasonal variation has a known influence on the transmission of several respiratory viral infections, its role in SARS-CoV-2 transmission remains unclear. As previous analyses have not accounted for the implementation of non-pharmaceutical interventions (NPIs) in the first year of the pandemic, they may yield biased estimates of seasonal effects. Building on two state-of-the-art observational models and datasets, we adapt a fully Bayesian method for estimating the association between seasonality and transmission in 143 temperate European regions. We find strong seasonal patterns, consistent with a reduction in the time-variable R t of 42.1% (95% CI: 24.7% – 53.4%) from the peak of winter to the peak of summer. These results imply that the seasonality of SARS-CoV-2 transmission is comparable in magnitude to the most effective individual NPIs but less than the combined effect of multiple interventions. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement J. T. Monrad acknowledges funding from the Augustinus Foundation, the Knud Hojgaard Foundation, the William Demant Foundation, the Aage and Johanne Louis-Hansen Foundation, and the Kai and Gunhild Lange Foundation. M. Sharma was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and a grant from the EA Funds programme. S. Mindermann's funding for graduate studies was from Oxford University and DeepMind. G.Leech was supported by the UKRI Centre for Doctoral Training in Interactive Artificial Intelligence (EP/S022937/1). S.Bhatt acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the U.K. Medical Research Council (MRC) and the U.K. Foreign, Commonwealth and Development Office (FCDO), under the MRC/FCDO Concordat agreement; is a part of the EDCTP2 program supported by the European Union; and acknowledges funding by Community Jameel. J.M. Brauner was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and by Cancer Research UK. S. Bhatt acknowledges The UK Research and Innovation (MR/V038109/1), the Academy of Medical Sciences Springboard Award (SBF004/1080), The MRC (MR/R015600/1), The BMGF (OPP1197730), Imperial College Healthcare NHS Trust- BRC Funding (RDA02), The Novo Nordisk Young Investigator Award (NNF20OC0059309) and The NIHR Health Protection Research Unit in Modelling Methodology. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: No approval required for research on fully anonymised data, as per the Central University Research Ethics Committee (CUREC) of the University of Oxford. https://researchsupport.admin.ox.ac.uk/governance/ethics/apply All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Spring 2020 dataset has been published in Brauner et al.: "The effectiveness of eight nonpharmaceutical interventions against COVID-19 in 41 countries". Fall-winter 2020 dataset is currently available upon request. The entire implementation is publicly available on GitHub. [https://github.com/gavento/covid\_seasonal\_Brauner][1] [https://github.com/gavento/covid\_seasonal\_Sharma][2] [1]: https://github.com/gavento/covid_seasonal_Brauner [2]: https://github.com/gavento/covid_seasonal_Sharma